Video

New Parkinson Disease Treatment

Patients with Parkinson disease experiencing “off” episodes on levodopa/carbidopa now have another treatment option.

There is now another option for patients with Parkinson disease. The FDA has approved Xadago (safinamide) tablets as an add-on treatment for patients taking levodopa/carbidopa.

In patients experiencing “off” episodes, safinamide has been shown in two clinical trials to be efficacious in reducing involuntary movement and improving motor function scores.

The most common side effects are falls, nausea, insomnia, and dyskinesia.

 

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Videos
Molly Abbott, BM BCh
Laren Becker, MD, PhD
David Shprecher, DO, MSci, FAAN
Pamela Zeilman, NP
 Esther Labib-Kiyarash, MSHA, CPHQ
Justin Martello, MD
William Ondo, MD
Jennifer Corcoran, MD
Marcia Pasqualini, PhD
Anissa Mitchell, LCSW
© 2025 MJH Life Sciences

All rights reserved.